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The pipelineTM embolization device (PED) is a braided, tubular, bimetallic 
endoluminal implant used for occlusion of intracranial aneurysms through 
flow disruption along the aneurysm neck. The authors report on two cas-
es of giant internal carotid artery aneurysm treated with the PED. In the 
first case, an aneurysm measuring 26.4 mm was observed at the C3-C4 
portion of the left internal carotid artery in a 64-year-old woman who 
underwent magnetic resonance imaging (MRI) for dizziness and diplopia. 
In the second case, MRI showed an aneurysm measuring 25 mm at the 
C4-C5 portion of the right internal carotid artery in a 39-year-old woman 
with right ptosis and diplopia. Each giant aneurysm was treated with de-
ployment of a PED (3.75 mm diameter/20 mm length and 4.5 mm diam-
eter/25 mm length, respectively). Nine months later, both cases showed 
complete radiological occlusion of the giant intracranial aneurysm and sac 
shrinkage. We suggest that use of the PED can be a therapeutic option 
for giant intracranial aneurysms.
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INTRODUCTION
The natural history of giant intracranial aneurysms in-
cludes high morbidity and mortality from rupture.27) 
Symptomatic lesions can be present in 50% of rupture 
cases, and the mortality rate is 60% in two years.6) These 
aneurysms are often found in the cavernous and para-
clinoid segments of the internal carotid artery (ICA).2) In 
endovascular treatment of giant aneurysms using coils, 
performance of complete packing is difficult, and the 
rates of recurrence are high.3)7)18)25) Although advanced 
coil techniques using a double catheter, assisted balloon 
or stent, and complex-shaped coils have improved the 
radiological complete occlusion, 7~26% recanalization of 
the aneurysm has been reported in several cases.4)8)21)
The pipelineTM embolization device (PED; eV3/Covidien, 
Plymouth, MN, USA) has been introduced as a new 
modality for diversion of flow from the parent artery 
into the sac. It is different from the traditional concept 
of packing in the sac for a barrier with coils. This de-
vice induces a compromise of the hemodynamic flow 
between the parent artery and aneurysm, producing 
spontaneous thrombosis in the sac and neointimal 
growth in the neck.11)12)14)23) We report on our experi-
ence with two cases in which the PED was used for 
treatment of giant internal carotid artery (ICA) aneur-
ysms for the first time in Korea.
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Fig. 1. A giant aneurysm located at the C3-C4 portion of the left internal carotid artery. Initial T2-weighted MRI (A), cerebral an-
giography (B), SPECT (C), after deployment of PED (D and E), CTA three months later (F), angiography six months later (G and H), 
CTA nine months later showing sac shrinkage (I). MRI = magnetic resonance imaging; SPECT = single photon emission computed 
tomography; PED = pipeline embolization device; CTA = computerized tomography angiography
CASE REPORTS
Case 1
A 64-year-old woman presented with left ptosis and 
lateral gaze restriction. Magnetic resonance imaging 
(MRI) showed a partially thrombosed giant aneurysm 
at the cavernous portion. Cerebral angiography showed 
that the maximal size and neck size of the aneurysm 
were 26.4 mm and 8.3 mm, respectively, at the C3-C4 
segment of the ICA. We performed the balloon-occlu-
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sion test (BOT) with single photon emission computed 
tomography (SPECT), which showed that the collater-
al flow was not sufficient. The patient was referred 
for PipelineTM stenting. Under general anesthesia, a 
7-French Flexor® Shuttle® guiding sheath (Cook Medical, 
Bloomington, IN, USA) was placed in the right ICA, and 
a 6-French Envoy® guiding catheter (Cordis Corporation, 
Bridgewater, NJ, USA) was placed coaxially through the 
shuttle for increased support. The Marksman® 0.027 mi-
crocatheter (ev3/Covidien, Plymouth, MN, USA) was 
navigated to the left middle cerebral artery using a 
Traxcess® 0.014 microguidewire (Microvention, Tustin, 
CA, USA). A PED (diameter, 3.75 mm; length, 20 mm; 
ev3/Covidien, Plymouth, MN, USA) was introduced 
and deployed, spanning the aneurysm neck and ach-
ieving maximal apposition to the ICA wall. Final an-
giography showed a decreased vortex flow in the 
aneurysm sac without thromboembolic complications. 
Three-month follow-up, computerized tomography an-
giography (CTA) showed that the PED has a good ap-
position to the vessel wall. Six-month follow-up an-
giography showed that the vortex flow into the sac 
had nearly disappeared and the vessel wall had been 
reconstructed using the PED. Nine months later, CTA 
showed progressive shrinkage of the aneurysm sac, 
and the symptoms of ptosis and diplopia showed 
slight improvement (Fig. 1).
Case 2
A 39-year-old woman presented with dizziness and 
intermittent diplopia. MRI showed a large (20.2 mm) 
aneurysm at the cavernous portion. During follow-up, 
she reported severe headache and continuous diplopia. 
CTA and cerebral angiography showed that the 
aneurysm had increased in size since one year earlier. 
The maximal size and neck size were 26.7 mm and 
6.4 mm, respectively, at the C4 segment of the ICA. 
During BOT, the patient reported visual disturbance 
during the hypotensive challenge test. She was also 
referred for PipelineTM stenting. The PED (diameter, 
4.5 mm; length, 25 mm; ev3/Covidien, Plymouth, 
MN, USA) was introduced and deployed, spanning 
the aneurysm neck. Post-angiography showed a 
well-implanted PED with contrast stasis in the aneur-
ysm sac. No treatment-related complications were 
noted. After three months, CTA showed contrast me-
dium filling a small portion of the sac. Six months lat-
er, cerebral angiography showed that the parent ar-
tery sustained a good flow patency and vessel re-
construction; the residual small filling portion dis-
appeared within nine months, however, the overall 
size was not changed with thrombosis. Fortunately, 
sixth nerve palsy showed slight improvement (Fig. 2).
Medication
Patients were pretreated with aspirin (100 mg/day) 
and clopidogrel (75 mg/day) for one week before 
PED deployment. During the procedure, intravenous 
heparin was administered at 50-100 U/kg for achieve-
ment of an activated clotting time of 250-300 seconds; 
this therapy was continued for 12 hours. After stent-
ing, intravenous dexamethasone was administered at 
20 mg/day for four days; subsequently, oral pre-
dnisolone was administered. Within 10 days, the oral 
medication was tapered as follows: 20 mg for six 
days, 15 mg for two days, 10 mg for one day, and 5 
mg for one day. Dual antiplatelet medication was 
maintained for six months, and mono-medication 
(aspirin or clopidogrel) was prescribed indefinitely. 
DISCUSSION
Interventionists encounter many difficulties in treat-
ment of giant intracranial aneurysms. In the early en-
dovascular treatment using only the coiling modality, 
retreatment was frequently required because complete 
occlusion of the aneurysm could not be achieved.7)18)25) 
Although combined use of a stent and balloon has 
improved the initial technique, the results are often 
not sustained because these aneurysms tend to re-
quire coil compaction and recanalization.3)4)8)21) In ad-
dition, in most cases, the orifice of the giant aneurysm 
is not a focal defect of the parent vessel wall but a 
segment of the parent vessel wall. In such cases, the 
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Fig. 2. A giant aneurysm located at the C4-C5 portion of the right internal carotid artery. Initial T2-weighted MRI (A), follow-up 
CTA (B), cerebral angiography (C), after deployment of PED (D and E), CTA three months later with small filling portion (F), an-
giography six months later (G) and (H), CTA nine months later without remnant sac (I). 
MRI = magnetic resonance imaging; PED = pipeline embolization device; CTA = computerized tomography angiography
conventional embolization technique, which involves 
filling the sac and covering the neck in order to dis-
rupt flow into and out of the aneurysm, has a low ef-
ficacy for treatment of these circumferentially in-
volved vessels. 
The PED (ev3/Covidien, Plymouth, MN, USA), a 
braided, tubular, bimetallic endoluminal implant com-
posed of 48 individual microfilaments prepared using 
25% platinum and 75% cobalt chromium, provides 
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30~35% metal coverage of the inner surface of the tar-
get vessel. This ratio is higher than that of conven-
tional stents, which provide 6.5~9.5% of metal surface 
area coverage. Due to the low porosity (0.02-0.05 
mm2) of this device, hemodynamic flow from the pa-
rent vessel cannot enter the aneurysm and sufficient 
scaffolding is provided to support neointimal re-
generation of the neck. Preliminary clinical ob-
servations and experimental studies have shown that 
stents with low porosity may induce a high resistance 
to flow into the aneurysm, leading to flow stagnation 
in the sac and promotion of thrombosis and sub-
sequent occlusion of the aneurysm.1)14)24) In a rabbit 
elastase aneurysm model, Kallmes et al.11)12) reported 
the occlusion rate of the PED and neointimal hyper-
plasia after stenting. Their second device (PED-2) pro-
vided approximately 35% of area coverage over the 
aneurysm neck. PED-2 achieved a superior occlusion 
rate (94% complete occlusion) compared with that of 
first-generation devices (53%) with 30% coverage. 
There were no cases of branch artery occlusion, either 
immediately after implantation or at follow-up. At six 
months, they harvested aneurysms and demonstrated 
that the tubular strut provides scaffolding for neo-
intimal regeneration across the aneurysm neck. This 
regenerated endothelium over the device resulted in a 
contiguous layer between the proximal and distal por-
tions of the parent artery in an in situ PED construct.
Lylyk et al.16) reported that in 53 patients with 63 
aneurysms treated using PED, a 95% complete angio-
graphic occlusion rate was achieved at 12 months of 
follow-up. Ninety four percent of the aneurysms 
arose from segmental lesions in which the vessel wall 
defect included more than 25% of the circumference 
of the parent artery, and 13% of the aneurysms were 
giant aneurysms. No major complications or recanali-
zation occurred during the study period. Szikora et 
al.26) reported that among 19 wide-neck aneurysms in 
18 patients treated with PED, the complete occlusion 
rate at six months of follow up was 94.4%. Nine cases 
were treated with a combination of PED and coils, 
however, all giant aneurysms (21.1%) were treated 
with PED alone. No difference in occlusion rate was 
observed between treatment using combined coil and 
that using PED alone. The morbidity and mortality 
rates were 5.6% each. Of particular interest, they 
showed that treatment with PED resulted in not only 
angiographic occlusion of the aneurysm but also re-
duction of the mass effect at the giant aneurysm. 
Saatci et al.22) reported the results of a large sin-
gle-center series treated with PED; among 255 aneur-
ysms in 191 patients, complete occlusion rates of 
91.2% and 95.2% were achieved at six and 24 months, 
respectively, with a permanent morbidity rate of 1% 
and mortality rate of 0.5%. Of these, 11.8% were giant 
aneurysms, and at six months of follow up, 90% of 
aneurysms were completely occluded.
Although use of the PED has been limited in Korea, 
several studies have reported unfavorable complications. 
The rate of minor events was 9~16.7% and mortality 
was 0~6.4%.5)9)13)15-17)22)26)28) On systematic review, stroke 
due to thromboembolism was 3.2% and that of in 
stent stenosis more than 50% was 3.5%.19) The perfo-
rator occlusion, which is a main concern related to the 
PED, was reported as 2.5% by multiple applied de-
vices, improper deployment, and resistance to anti-
platelet medication.15)20)26)28) In addition, McAuliffe et 
al.17) experienced two cases of PED migration through 
the initial learning curve. After treatment with PED, 
intracranial hemorrhage of 0~6% was reported and 
possible causes were aneurysm rupture during the 
procedure, hemorrhagic transformation from ischemic 
tissue, inflammation of aneurysm wall, and foreign 
body's reaction.5)10)20)22)26) 
In our experience using the PED for treatment of 
two giant intracranial aneurysms, the device flexibility 
was satisfactory with good stability. In both cases, the 
device was successfully apposed to the parent vessel 
wall without difficulty using standard microcatheters. 
Follow-up results confirmed that the PED affects the 
amount of blood flow into the sac and induces throm-
bosis in the sac. 
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CONCLUSION
Treatment of giant aneurysms using open surgical 
or conventional endovascular methods is often risky 
and challenging. Based on our experience of using the 
PED, we suggest that it could be another modality for 
treatment of giant intracranial aneurysms.
Disclosure
The authors report no conflict of interest concerning 
the findings specified in this paper.
REFERENCES
1. Augsburger L, Farhat M, Reymond P, Fonck E, Kulcsar 
Z, Stergiopulos N, et al. Effect of flow diverter porosity 
on intraaneurysmal blood flow. Klin Neuroradiol. 2009 
Aug;19(3):204-14.
2. Barrow DL, Alleyne C. Natural history of giant intra-
cranial aneurysms and indications for intervention. Clin 
Neurosurg. 1995;42:214-44.
3. Berenstein A, Song JK, Niimi Y, Namba K, Heran NS, 
Brisman JL, et al. Treatment of cerebral aneurysms with 
hydrogel-coated platinum coils (HydroCoil): early sin-
gle-center experience. AJNR Am J Neuroradiol. 2006 
Oct;27(9):1834-40.
4. Fiorella D, Albuquerque FC, Deshmukh VR, McDougall 
CG. Usefulness of the Neuroform stent for the treatment 
of cerebral aneurysms: results at initial (3-6-mo) follow-up. 
Neurosurgery. 2005 Jun;56(6):1191-201; discussion 1201-2.
5. Fischer S, Vajda Z, Aguilar Perez M, Schmid E, Hopf 
N, Bazner H, et al. Pipeline embolization device (PED) 
for neurovascular reconstruction: initial experience in the 
treatment of 101 intracranial aneurysms and dissections. 
Neuroradiology. 2012 Apr;54(4):369-82.
6. Fujita K, Yamashita H, Masumura M, Nishizaki T, 
Tamaki N, Matsumoto S. [Natural history of giant intra-
cranial aneurysms]. No Shinkei Geka. 1988 Mar;16(3):225-31. 
Japanese.
7. Gruber A, Killer M, Bavinzski G, Richling B. Clinical 
and angiographic results of endosaccular coiling treat-
ment of giant and very large intracranial aneurysms: a 
7-year, single-center experience. Neurosurgery. 1999 
Oct;45(4):793-803; discussion 803-4.
8. Hauck EF, Welch BG, White JA, Replogle RE, Purdy 
PD, Pride LG, et al. Stent/coil treatment of very large 
and giant unruptured ophthalmic and cavernous aneurysms. 
Surg Neurol. 2009 Jan;71(1):19-24; discussion 24.
9. Hirsch JA, Chandra RV, Leslie-Mazwi TM. Pipeline, 
aneurysms and the FDA. J Neurointerv Surg. 2012 
Jul;4(4):314; author reply 314.
10. Hu YC, Deshmukh VR, Albuquerque FC, Fiorella D, 
Nixon RR, Heck DV, et al. Histopathological assessment 
of fatal ipsilateral intraparenchymal hemorrhages after 
the treatment of supraclinoid aneurysms with the Pipeline 
Embolization Device. J Neurosurg. 2014 Feb;120(2):365-74.
11. Kallmes DF, Ding YH, Dai D, Kadirvel R, Lewis DA, Cloft 
HJ. A new endoluminal, flow-disrupting device for treat-
ment of saccular aneurysms. Stroke. 2007 Aug;38(8):2346-52.
12. Kallmes DF, Ding YH, Dai D, Kadirvel R, Lewis DA, 
Cloft HJ. A second-generation, endoluminal, flow-dis-
rupting device for treatment of saccular aneurysms. 
AJNR Am J Neuroradiol. 2009 Jun;30(6):1153-8.
13. Kan P, Siddiqui AH, Veznedaroglu E, Liebman KM, 
Binning MJ, Dumont TM, et al. Early postmarket results 
after treatment of intracranial aneurysms with the pipe-
line embolization device: a U.S. multicenter experience. 
Neurosurgery. 2012 Dec;71(6):1080-7; discussion 1087-8.
14. Lieber BB, Stancampiano AP, Wakhloo AK. Alteration of he-
modynamics in aneurysm models by stenting: influence of 
stent porosity. Ann Biomed Eng. 1997 May-Jun;25(3):460-9.
15. Lubicz B, Collignon L, Raphaeli G, De Witte O. Pipeline 
flow-diverter stent for endovascular treatment of intra-
cranial aneurysms: preliminary experience in 20 patients 
with 27 aneurysms. World Neurosurg. 2011 Jul-Aug;76 
(1-2):114-9.
16. Lylyk P, Miranda C, Ceratto R, Ferrario A, Scrivano E, 
Luna HR, et al. Curative endovascular reconstruction of 
cerebral aneurysms with the pipeline embolization de-
vice: the Buenos Aires experience. Neurosurgery. 2009 
Apr;64(4):632-42; discussion 642-3.
17. McAuliffe W, Wycoco V, Rice H, Phatouros C, Singh TJ, 
Wenderoth J. Immediate and midterm results following 
treatment of unruptured intracranial aneurysms with the 
pipeline embolization device. AJNR Am J Neuroradiol. 
2012 Jan;33(1):164-70.
18. Murayama Y, Nien YL, Duckwiler G, Gobin YP, Jahan 
R, Frazee J, et al. Guglielmi detachable coil embolization 
of cerebral aneurysms: 11 years' experience. J Neurosurg. 
2003 May;98(5):959-66.
19. Murthy SB, Shah S, Venkatasubba Rao CP, Bershad EM, 
Suarez JI. Treatment of unruptured intracranial aneur-
ysms with the pipeline embolization device. J Clin 
Neurosci. 2014 Jan;21(1):6-11.
20. Nelson PK, Lylyk P, Szikora I, Wetzel SG, Wanke I, 
Fiorella D. The pipeline embolization device for the in-
tracranial treatment of aneurysms trial. AJNR Am J 
Neuroradiol. 2011 Jan;32(1):34-40.
21. Piotin M, Blanc R, Spelle L, Mounayer C, Piantino R, 
Schmidt PJ, et al. Stent-assisted coiling of intracranial 
aneurysms: clinical and angiographic results in 216 con-
secutive aneurysms. Stroke. 2010 Jan;41(1):110-5.
22. Saatci I, Yavuz K, Ozer C, Geyik S, Cekirge HS. 
Treatment of intracranial aneurysms using the pipeline 
flow-diverter embolization device: a single-center experi-
ence with long-term follow-up results. AJNR Am J 
Neuroradiol. 2012 Sep;33(8):1436-46.
23. Sadasivan C, Lieber BB, Cesar L, Miskolczi L, Seong J, 
Wakhloo AK. Angiographic assessment of the perform-
ance of flow divertors to treat cerebral aneurysms. Conf 
Proc IEEE Eng Med Biol Soc. 2006;1:3210-3.
24. Seshadhri S, Janiga G, Beuing O, Skalej M, Thevenin D. 
Impact of stents and flow diverters on hemodynamics 
in idealized aneurysm models. J Biomech Eng. 2011 
PED FOR GIANT INTRACRANIAL ANEURYSMS
118  J Cerebrovasc Endovasc Neurosurg
Jul;133(7):071005.
25. Sluzewski M, Menovsky T, van Rooij WJ, Wijnalda D. 
Coiling of very large or giant cerebral aneurysms: 
long-term clinical and serial angiographic results. AJNR 
Am J Neuroradiol. 2003 Feb;24(2):257-62.
26. Szikora I, Berentei Z, Kulcsar Z, Marosfoi M, Vajda ZS, 
Lee W, et al. Treatment of intracranial aneurysms by 
functional reconstruction of the parent artery: the 
Budapest experience with the pipeline embolization 
device. AJNR Am J Neuroradiol. 2010 Jun;31(6):1139-47.
27. Wiebers DO, Whisnant JP, Huston J 3rd, Meissner I, 
Brown RD Jr, Piepgras DG, et al. Unruptured intra-
cranial aneurysms: natural history, clinical outcome, and 
risks of surgical and endovascular treatment. Lancet. 
2003 Jul;362(9378):103-10.
28. Yu SC, Kwok CK, Cheng PW, Chan KY, Lau SS, Lui 
WM, et al. Intracranial aneurysms: midterm outcome of 
pipeline embolization device-a prospective study in 143 
patients with 178 aneurysms. Radiology. 2012 Dec;265(3) 
:893-901.
